Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.

Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR.

Genes Dev. 2007 Jun 1;21(11):1396-408. Epub 2007 May 17.

2.

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

Riely GJ, Politi KA, Miller VA, Pao W.

Clin Cancer Res. 2006 Dec 15;12(24):7232-41. Review.

3.

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J.

Cancer Cell. 2006 Nov;10(5):425-35. Erratum in: Cancer Cell. 2009 Nov 6;16(5):448.

4.

Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.

Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T.

Cancer Res. 2006 Nov 1;66(21):10517-24.

5.

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.

Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M.

J Clin Oncol. 2006 Nov 1;24(31):5079-90. Review.

PMID:
17075127
6.

STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis.

Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS.

Gastroenterology. 2006 Oct;131(4):1073-85. Epub 2006 Jul 24.

PMID:
17030178
7.

Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.

Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J.

Cancer Res. 2006 Oct 1;66(19):9714-21.

8.

Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma.

Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS.

Neoplasia. 2006 Sep;8(9):733-46.

9.

Significance of interleukin-6 (IL-6) in breast cancer (review).

Knüpfer H, Preiss R.

Breast Cancer Res Treat. 2007 Apr;102(2):129-35. Epub 2006 Aug 23. Review.

PMID:
16927176
10.
11.

Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.

Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H; Cancer and Leukemia Group B..

Breast Cancer Res Treat. 2006 Dec;100(3):301-8. Epub 2006 Jun 14.

PMID:
16773437
12.
13.

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE.

Genes Dev. 2006 Jun 1;20(11):1496-510. Epub 2006 May 16.

14.

Interleukin-6 trans-signalling in chronic inflammation and cancer.

Scheller J, Ohnesorge N, Rose-John S.

Scand J Immunol. 2006 May;63(5):321-9. Review.

15.
17.

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.

Yeh HH, Lai WW, Chen HH, Liu HS, Su WC.

Oncogene. 2006 Jul 20;25(31):4300-9. Epub 2006 Mar 6.

PMID:
16518408
18.

Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer.

Haura EB, Livingston S, Coppola D.

Clin Lung Cancer. 2006 Jan;7(4):273-5.

PMID:
16512982
19.

Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD.

Cancer Res. 2006 Feb 15;66(4):2116-28.

20.

Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression.

Spangenburg EE, Brown DA, Johnson MS, Moore RL.

J Physiol. 2006 May 1;572(Pt 3):839-48.

Supplemental Content

Support Center